{"id":{"repo_id":"radboud","oai_identifier":"oai:repository.ubn.ru.nl:2066/145305"},"canonical_url":"https://search.dev.ndltd.org/etd/radboud/oai:repository.ubn.ru.nl:2066/145305","repository":{"repo_id":"radboud","name":"Radboud University Nijmegen","base_url":"https://repository.ubn.ru.nl/oai/request"},"display":{"title":"The immune response in Q fever.","abstract":"Contains fulltext : 145305.pdf (Publisher’s version ) (Open Access)","abstract_html":"Contains fulltext : 145305.pdf (Publisher’s version ) (Open Access)","abstract_has_math":false,"creators":["Schoffelen, T."],"institution":"S.l. : s.n.","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Meer, J.W.M. van der","Netea, M.G.","Deuren, M. van","Sprong, T."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015","date_published":"2015","updated_at":"2026-07-24T04:03:01Z","subjects":["Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["9789462598546"],"render_values":[{"text":"9789462598546","href":null,"code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2066/145305","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Meer, J.W.M. van der","Netea, M.G.","Deuren, M. van","Sprong, T."]},{"key":"dc:creator","label":"Author","values":["Schoffelen, T."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015"]},{"key":"dc:publisher","label":"Institution","values":["S.l. : s.n."]},{"key":"dc:type","label":"Dc Type","values":["Doctoral thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://repository.ubn.ru.nl//bitstream/handle/2066/145305/145305.pdf","https://hdl.handle.net/2066/145305","9789462598546"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Contains fulltext : 145305.pdf (Publisher’s version ) (Open Access)","Q fever is an infection caused by the bacterium Coxiella burnetii. A large outbreak of Q fever occurred in the Netherlands between 2007 and 2010, in which infected goats and sheep were the source of human infections. In some people, so-called ‘chronic Q fever’ develops, which mainly manifests as endocarditis, infection of vascular prosthesis or aortic aneurysms, or both. We studied the immune response against C. burnetii in blood of healthy individuals, chronic Q fever patients and people with a past Q fever infection. Immune cells of chronic Q fever patients showed an increased production of ‘interferon-gamma’, a key signalling molecule. We concluded that, in contrast to what had generally been assumed, the interferon-gamma mediated immune response is not defect in chronic Q fever. Subsequently, we used the measurement of interferon-gamma production and other cell-signalling molecules (‘cytokines’) in blood in-vitro for diagnostic purposes. We found that these kind of blood tests can accurately detect a past or chronic Q fever infection. This valuable new diagnostic tool is currently being developed to a commercial blood test for Q fever infection. In a screening-study among patients with rheumatoid arthritis (RA) with immunomodulating drugs, we studied the risk for chronic Q fever. We found that RA patients are at increased risk for chronic Q fever compared to the general population. We advised to carefully check for chronic Q fever in these patients when they have been exposed to C. burnetii. We alse studied the unique Q fever vaccination campaign in the Netherlands in 2011, in which 1370 people with increased risk for chronic Q fever were vaccinated. This was the first time worldwide that such a large population at risk was being vaccinated against Q fever. We could conclude that vaccination was safe, but many vaccinees reported local skin reactions. We measured the immune response in blood of vaccinees 6 and 12 months after vaccination and found overall only a limited immune reaction to C. burnetii. We calculated retrospectively that only 11% of people at risk have been vaccinated in this 2011 campaign.","Radboud Universiteit Nijmegen, 02 november 2015","Promotores : Meer, J.W.M. van der, Netea, M.G. Co-promotores : Deuren, M. van, Sprong, T."]},{"key":"dc:title","label":"Title","values":["The immune response in Q fever."]}]}],"canonical_facts":{"dc:contributor":["Meer, J.W.M. van der","Netea, M.G.","Deuren, M. van","Sprong, T."],"dc:creator":["Schoffelen, T."],"dc:date":["2015"],"dc:description":["Contains fulltext : 145305.pdf (Publisher’s version ) (Open Access)","Q fever is an infection caused by the bacterium Coxiella burnetii. A large outbreak of Q fever occurred in the Netherlands between 2007 and 2010, in which infected goats and sheep were the source of human infections. In some people, so-called ‘chronic Q fever’ develops, which mainly manifests as endocarditis, infection of vascular prosthesis or aortic aneurysms, or both. We studied the immune response against C. burnetii in blood of healthy individuals, chronic Q fever patients and people with a past Q fever infection. Immune cells of chronic Q fever patients showed an increased production of ‘interferon-gamma’, a key signalling molecule. We concluded that, in contrast to what had generally been assumed, the interferon-gamma mediated immune response is not defect in chronic Q fever. Subsequently, we used the measurement of interferon-gamma production and other cell-signalling molecules (‘cytokines’) in blood in-vitro for diagnostic purposes. We found that these kind of blood tests can accurately detect a past or chronic Q fever infection. This valuable new diagnostic tool is currently being developed to a commercial blood test for Q fever infection. In a screening-study among patients with rheumatoid arthritis (RA) with immunomodulating drugs, we studied the risk for chronic Q fever. We found that RA patients are at increased risk for chronic Q fever compared to the general population. We advised to carefully check for chronic Q fever in these patients when they have been exposed to C. burnetii. We alse studied the unique Q fever vaccination campaign in the Netherlands in 2011, in which 1370 people with increased risk for chronic Q fever were vaccinated. This was the first time worldwide that such a large population at risk was being vaccinated against Q fever. We could conclude that vaccination was safe, but many vaccinees reported local skin reactions. We measured the immune response in blood of vaccinees 6 and 12 months after vaccination and found overall only a limited immune reaction to C. burnetii. We calculated retrospectively that only 11% of people at risk have been vaccinated in this 2011 campaign.","Radboud Universiteit Nijmegen, 02 november 2015","Promotores : Meer, J.W.M. van der, Netea, M.G. Co-promotores : Deuren, M. van, Sprong, T."],"dc:identifier":["https://repository.ubn.ru.nl//bitstream/handle/2066/145305/145305.pdf","https://hdl.handle.net/2066/145305","9789462598546"],"dc:publisher":["S.l. : s.n."],"dc:subject":["Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences"],"dc:title":["The immune response in Q fever."],"dc:type":["Doctoral thesis"]},"updated_at":"2026-07-24T04:03:01Z"}